The mood at the annual meeting of the American Society of Cell and Gene Therapy isn’t amazing. The biotech market has been ...

In June, the Centers for Medicare & Medicaid Services (CMS) will name the participating states for the agency’s new Cell and ...

Gene therapies offer incredible promise for treating diseases with a genetic component. Several gene therapies are already ...

Future treatments for DEB are expected to drive the sector’s growth. The global dermatological cell and gene therapy (CGT) ...

Healthcare providers are exploring ways to reduce patient travel through a growing trend of expanding sites of administration ...

2025 — A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps ...

The scientists at the University of California, San Francisco and Johns Hopkins University in Baltimore injected an antisense ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

Q1 2025 Management View Joseph Burnett, President and Chief Executive Officer, stated that "2025 is off to a terrific start here at ClearPoint Neuro as we have officially entered the third phase of ...

Plans expect cell and gene therapies to pose a moderate or major financial challenge in the next two to three years, ...

Cell and gene therapies offer potential new therapeutics but are currently constrained by complex and inefficient manufacturing strategies.

ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now ...